According to reports by Benzinga, a research report on Tuesday suggested that Morgan Stanley increased the price target on Ascendis Pharma A/S (NASDAQ:ASND) from $179.00 to $194.00. The company’s stock has received an ‘overweight’ rating from the brokerage. The price target set by Morgan Stanley indicates a 21.33% potential shift from the current price of the stock.
Ascendis Pharma A/S (NASDAQ:ASND)- Analysts’ Opinion
Several opinions have been showered by research analysts on Ascendis Pharma A/S (NASDAQ:ASND). On Wednesday, 2nd September, Zacks Investment Research dropped the rating of the firm from ‘hold’ to ‘sell.’ Wedbush increased the price target on the biotechnology company from $187.00 to $206.00. It also issued an ‘outperform’ rating to Ascendis, suggested a research report on Wednesday, 30th September.
The rating of NASDAQ:ASND was reduced from ‘buy’ to ‘hold’ rating by BidaskClub. A research report on 14th September, Monday said that JPMorgan Chase & Co. assumed coverage on the company’s shares. An ‘overweight’ rating was issued by JP Morgan. A research report on Friday, 28th August said that the Credit Suisse Group raised the price target on Ascendis Pharma A/S (NASDAQ:ASND) from $154.00 to $158.00. It also issued an ‘outperform’ rating.
Ascendis has received a ‘sell’ rating from one analyst, a ‘hold’ rating from one analyst, and a ‘buy’ rating from twelve analysts.